Dyadic highlights accelerated interest in C1 biomanufacturing platform

Dyadic International reports growing interest in its C1 protein production platform for rapid vaccine and antibody manufacturing amid Ebola preparedness efforts. The platform can progress from viral gene sequence to purified antigen in approximately 15 days, positioning the company to address urgent global health manufacturing challenges.